| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Ginsenoside F5 targets multiple cellular pathways. It is known to modulate immune responses, protect against oxidative stress, and regulate cellular signaling pathways linked to apoptosis and proliferation. The compound has been identified as a potential ligand for the ADGRG3/GPR97 receptor, which is associated with cancer and immune function. Its pro-apoptotic activity against leukemia cells suggests involvement in mitochondrial or death receptor pathways.
|
|---|---|
| ln Vitro |
Ginsenoside F5 demonstrates significant in vitro anticancer activity. It remarkably inhibits the growth of HL-60 human leukemia cells by inducing apoptosis. The compound exhibits antioxidant activity, protecting cells from oxidative stress, and anti-inflammatory effects by modulating immune responses. Its ability to regulate cellular signaling pathways involved in apoptosis and proliferation has been documented in various in vitro models.
|
| ln Vivo |
In vivo activity of ginsenoside F5 has been suggested by its diverse pharmacological activities, including anti-inflammatory, antioxidant, and anticancer effects. The compound's ability to modulate immune responses and protect against oxidative stress in vitro suggests potential for in vivo efficacy in models of inflammation and oxidative damage. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for ginsenoside F5 include evaluating its interaction with the ADGRG3/GPR97 receptor. Binding affinity can be assessed using surface plasmon resonance or radioligand binding assays. The compound's antioxidant activity can be measured using DPPH or ABTS radical scavenging assays. Its effects on apoptosis pathways can be evaluated by measuring caspase activity or mitochondrial membrane potential in treated cells.
|
| Cell Assay |
In vitro cellular assays for ginsenoside F5 involve treating HL-60 leukemia cells or other cancer cell lines with varying concentrations of the compound. Cell viability is assessed using MTT or other assays. Apoptosis is evaluated by Annexin V staining, caspase activity assays, or DNA fragmentation analysis. Anti-inflammatory activity can be assessed by measuring cytokine production in activated immune cells.
|
| Animal Protocol |
In vivo animal experiments for ginsenoside F5 are not extensively documented. If used in animal models, typical protocols would involve administering the compound to models of cancer, inflammation, or oxidative stress and evaluating efficacy by measuring tumor growth, inflammatory markers, or oxidative damage biomarkers. Further studies are needed to characterize its in vivo efficacy and safety.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for ginsenoside F5 are limited. As a ginsenoside, it may have limited oral bioavailability due to poor absorption and extensive metabolism. The compound is soluble in DMSO. Further pharmacokinetic studies are needed to determine its bioavailability, half-life, and tissue distribution.
|
| Toxicity/Toxicokinetics |
Toxicological data for ginsenoside F5 are limited. As a natural product-derived compound, it is generally considered to have low toxicity, but comprehensive toxicological studies have not been reported. Standard laboratory safety precautions should be followed when handling this compound. It is intended for research use only.
|
| References | |
| Additional Infomation |
Ginsenoside F5 is a triterpenoid saponin. It has been reported that ginseng contains ginsenoside F5, and relevant data is available for reference.
Ginsenoside F5 (CAS#: 189513-26-6) has the molecular formula C41H70O13 and a molecular weight of 770.99 g/mol. Its chemical name is (2S,3R,4S,5S,6R)-2-{[(2S)-2-[(1S,3aR,3bR,5S,5aR,7S,9aR,9bR,11R,11aR)-5,7,11-trihydroxy-3a,3b,6,6,9a-pentamethyl-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-en-2-yl]oxy}-6-({[(2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}methyl)oxane-3,4,5-triol. Purity is ≥98%. |
| Molecular Formula |
C41H70O13
|
|---|---|
| Molecular Weight |
770.99
|
| Exact Mass |
770.481
|
| CAS # |
189513-26-6
|
| PubChem CID |
46887590
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
885.5±65.0 °C at 760 mmHg
|
| Flash Point |
489.3±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.597
|
| LogP |
5.87
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
54
|
| Complexity |
1360
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO[C@H]6[C@@H]([C@H]([C@@H](O6)CO)O)O)O)O)O)C
|
| InChi Key |
KWRQPASKWCJCPI-DOGUGFTJSA-N
|
| InChi Code |
InChI=1S/C41H70O13/c1-20(2)10-9-13-41(8,54-36-33(50)31(48)30(47)25(53-36)19-51-35-32(49)29(46)24(18-42)52-35)21-11-15-39(6)28(21)22(43)16-26-38(5)14-12-27(45)37(3,4)34(38)23(44)17-40(26,39)7/h10,21-36,42-50H,9,11-19H2,1-8H3/t21-,22+,23-,24-,25+,26+,27-,28-,29-,30+,31-,32+,33+,34-,35+,36-,38+,39+,40+,41-/m0/s1
|
| Chemical Name |
(2R,3S,4S,5R,6S)-2-[[(2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-6-[(2S)-6-methyl-2-[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,6,12-trihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]hept-5-en-2-yl]oxyoxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (129.70 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2970 mL | 6.4852 mL | 12.9703 mL | |
| 5 mM | 0.2594 mL | 1.2970 mL | 2.5941 mL | |
| 10 mM | 0.1297 mL | 0.6485 mL | 1.2970 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
